Processing your request


please wait...

Case Page

 

Case Status:    DISMISSED    
On or around 11/13/2019 (Notice of voluntarily dismissal)

Filing Date: September 11, 2019

According to the Complaint, Genomic Health, Inc. is a healthcare company that provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

On July 28, 2019, Genomic Health and Exact Sciences announced that they had executed a definitive Agreement and Plan of Merger, pursuant to which Exact Sciences, through its wholly owned subsidiary Merger Sub, would acquire all the outstanding shares of common stock of Genomic Health in a mixed stock and cash transaction whereby each share of Genomic Health would be converted into the right to receive (a) $27.50 in cash, without interest, and (b) a number of shares of common stock, par value $0.01 per share, of Exact Sciences equal to (i) 0.36854, if the average of the volume-weighted average prices per share of Exact Sciences Common Stock on the Nasdaq Stock Market for each of the fifteen consecutive trading days ending immediately prior to the closing date is equal to or greater than $120.75, (ii) an amount equal to the quotient obtained by dividing $44.50 by the measurement price if the measurement price is greater than $98.79 but less than $120.75, and (iii) 0.45043, if the measurement price is equal to or less than $98.79, less any applicable withholding taxes.

On August 30, 2019, Defendants caused the filing of a Form S-4 Registration Statement with the United States Securities and Exchange Commission in support of the Proposed Transaction. The Complaint alleges that the Registration Statement is materially misleading and incomplete. The Complaint further alleges that Defendants have breached their fiduciary duties to Genomic Health stockholders by, inter alia, failing to maximize the value stockholders received in exchange for their shares.

This case was voluntarily dismissed on November 13, 2019.

Protected Content


Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.